Breaking News: Todos Medical Provides Strategic Outlook | Financial Buzz

Breaking News: Todos Medical Provides Strategic Outlook

Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today provided a corporate update to the market, as well as an outlook for the Company as it heads into 2021.

COVID-19 Testing Sets the stage for the future 

Todos recently completed the installation of two (2) Tecan® liquid handlers at its largest lab client in Wisconsin, thereby providing the lab liquid handlers in addition to automated extraction systems. After optimizing the workflows following the installation, we are confident this lab will be able to process up to 20,000 qPCR tests per day, with the lab now operating 24 hours per day, seven (7) days a week. This PCR testing capacity positions the lab to be able to increase sample inflows from its contract with the State of Wisconsin by up to 450%, which in turn will significantly increase order flow for Todos’ PCR testing consumables.

Additionally, we are preparing to complete the installation of a similar lab automation workflow process at another lab in Brooklyn, NY in the month of December, which will bring that lab’s testing capacity to 20,000 PCR tests per day. Taken together, we are demonstrating Todos’ ability to provide lab clients with automated workflows that can achieve high-throughput PCR testing capacity, coupled with the fact that this is a repeatable model that can significantly drive revenue. We intend to strategically scale existing clients and bring on new clients that have developed solid contracts for sample processing that will allow them to order large volumes of tests per day, leading to increased PCR sales for Todos.

As PCR testing continues to grow, recent advances in vaccine development will drive immune testing to understand whether immunity has been attained in individuals, either by prior COVID-19 infection or COVID-19 vaccination. Todos has established relationships with leading companies developing next-generation immune-based blood testing, and we intend to add these tests to our offering as they gain regulatory approval. Additionally, our proprietary 3CL protease test is in the final stages of testing before launch of lab-based test that will be complementary to existing PCR testing by confirming the activity status of the virus-positive patients. This assay will give better understanding of whether a patient remains contagious following quarantine or therapeutic intervention, and whether the Company’s proprietary dietary supplement Tollovid® could have an impact on the length of time a person remains infected. A clinical trial for Tollovid is being prepared in Israel.

Our business model is now set on offering genetic and immune testing reagents & kits to our clients, as the genetic testing capabilities labs are acquiring now in response to the COVID-19 crisis will allow them to expand their offerings to make available more cost-effective, scalable, genetic and immunology testing solutions to the market in the future. We believe this could drive the next wave of innovation in the US laboratory industry and give rise to better health information that will empower patients and physicians to make better decisions that will improve outcomes and reduce costs. The infrastructure required to turn the promise of personalized medicine into a reality is largely being pushed forward in response to COVID-19, and we see this as a megatrend that will continue well into the future.

We believe the mobile testing labs we have been helping advance have a similar opportunity to improve the landscape for testing in the United States by creating a proprietary outlet for novel testing solutions that will further support the nation’s testing infrastructure. Bringing testing forward in a new, more personalized way that reduces wait times and is agile enough to be deployed anywhere will survive the pandemic and will ultimately provide another key distribution channel for our testing solutions.

Todos’ Breast Cancer testing will become more central in 2021

2020 forced Todos to establish its commercial testing operations initially focused on COVID-19. As we head into a long winter where we expect cases to spike to record levels before vaccination programs can hopefully help reduce the severity of the pandemic, we are also beginning to think about the post-pandemic future and how Todos can establish itself as an important player in the diagnostic testing business for the long-term. As such, we are focused on utilizing the opportunity provided by COVID-19 testing to position for launch of diagnostic testing through the commercial outlets we are establishing now.

We intend to focus our pipeline initially on breast cancer where we are building up significant intellectual property around our proprietary TBIA/FTIR platform, and commercial infrastructure by way of the strategic acquisition of Provista Diagnostics, so that we can consolidate our commercial opportunity and optimize assay performance as we go to market in 2021 in breast cancer blood testing.

Summary

2020 has really forced Todos to focus on establishing commercial operations so that we can position the Company to capture scalable revenue in the face of steep competition. As we begin to significantly execute on the COVID revenue opportunity, we are leveraging our proprietary distribution channels in such a way that we will be able to deploy our other proprietary testing products through those channels to be able to scale our more proprietary testing solutions that could have an impact far beyond COVID-19.

We are working hard on closing out 2020 on a high note, and expect 2021 to be a transformational year for Todos as we build upon the initial commercial success we are seeing in 2020. We are excited with the opportunity before us to dramatically improve testing in the United States.

For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com   

For testing and PPE inquiries, please email sales@todosmedical.com .

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Additionally, Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed strategic partnerships with Integrated Health LLC, MOTOPARA Foundation to deploy mobile COVID-19 testing in the United States.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has signed a six-month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has agreed to five million restricted shares, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.